July 19, 2022
Press Releases
BELOIT, Wis., July 19, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing of a long-term supply agreement with Clovis Oncology, Inc. (NASDAQ: CLVS) for the therapeutic medical radioisotope, actinium-225 (Ac-225). Under terms of the agreement, […]
Read more »
June 20, 2022
Press Releases
BELOIT, Wis., June 20, 2022 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the promotion of one of its key executives. The announcement comes as NorthStar reaches a pivotal stage in its growth and industry influence. Dr. Frank Scholz has been named […]
Read more »
June 7, 2022
Press Releases
− Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added (n.c.a.) Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors − BELOIT, Wis., and Cambridge, Mass., June 7, 2022 – NorthStar Medical Radioisotopes, LLC […]
Read more »
May 24, 2022
Press Releases
BELOIT, Wis., May 24, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Monica Andersen as Vice President, Human Resources. In this new position, she will hold responsibility for the Company’s Human Resources and Organizational […]
Read more »
March 29, 2022
Press Releases
− NorthStar positioned for continued strong growth and setting leadership standards for domestic, environmentally sustainable radioisotope production across its portfolio to meet needs of health systems, radiopharmacies and patients – − NorthStar continues as the only U.S. commercial producer of diagnostic imaging radioisotopes non-uranium molybdenum-99 (Mo-99)/technetium-99m (Tc-99m), for more than three years − − Company […]
Read more »
March 9, 2022
Press Releases
− NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in Convergent’s lead, dual-targeted radionuclide program for prostate cancer, CONV01-α − BELOIT, Wis., and CAMBRIDGE, Mass., March 9, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Convergent Therapeutics, […]
Read more »
March 8, 2022
Press Releases
BELOIT, Wis., March 8, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will participate in an upcoming corporate event hosted by Oppenheimer & Co. Inc. […]
Read more »
November 29, 2021
Press Releases
BELOIT, Wis., November 29, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Adam D. Lynch as Vice President, Corporate Development and External Affairs. In this new position, he brings to the Company more than […]
Read more »
November 18, 2021
Press Releases
BELOIT, Wis., USA and Louvain-La-Neuve, Belgium, November 18, 2021 – NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announced a new contract in which NorthStar […]
Read more »
October 14, 2021
Press Releases
− Marking Company’s progress in advancing innovative and environmentally sound production of diagnostic imaging and therapeutic radioisotopes for the United States and Wisconsin − BELOIT, Wis., October 14, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, hosted a growth […]
Read more »
October 7, 2021
Press Releases
BELOIT, Wis., October 7, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, is proud to announce the launch of its newly redesigned corporate website. The new site includes increased functionality and a number of enhancements. Expanded content includes latest […]
Read more »
September 8, 2021
Press Releases
BELOIT, Wis. and INDIANAPOLIS, Ind., September 8, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing […]
Read more »
September 8, 2021
Press Releases
BELOIT, Wis., September 8, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held […]
Read more »
August 30, 2021
Press Releases
− Supports neutron capture and accelerator production technology to further increase NorthStar’s production capacity of commercially available non-uranium based Mo-99 − BELOIT, Wis., August 30, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, announced today that it has been […]
Read more »
August 3, 2021
Press Releases
− Collaboration will produce and distribute Iodine-123 (I-123) capsules, the proven radiopharmaceutical standard in diagnostic imaging studies for thyroid disease – BELOIT, Wis. and Arlington Heights, Ill., August 3, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE […]
Read more »
June 21, 2021
Press Releases
BELOIT, Wis., June 21, 2021 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the appointment of Frank Scholz, Ph.D., as Senior Vice President and Chief Operating Officer. In this new position, he brings more than 20 years of relevant operational experience in […]
Read more »
June 10, 2021
Press Releases
BELOIT, Wis., June 10, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, being held in a virtual format from June 11 −15, 2021. NorthStar […]
Read more »
May 26, 2021
Press Releases
WILMETTE, Ill. and BELOIT, Wis., May 26, 2021 – Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional composition of matter patent titled “Urokinase Plasminogen Activator Receptor-Targeted Radiopharmaceutical” covering a radiotherapeutic consisting of Monopar’s proprietary antibody MNPR-101 bound to Actinium-225 (Ac-225) via the metal binding agent PCTA. This […]
Read more »
May 25, 2021
Press Releases
− Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others − BELOIT, Wis. and Sydney, Australia – May 25, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical […]
Read more »
May 24, 2021
Press Releases
– Potential to significantly improve the yield of Actinium-based radiopharmaceuticals CHICAGO, Ill. and BELOIT, Wis., May 24, 2021 – Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, Ill) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis), today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled “Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods […]
Read more »
May 11, 2021
Press Releases
− NorthStar, leading the way as the sole U.S. commercial supplier of molybdenum-99 (Mo-99), continues expansion efforts for increased capacity and ongoing reliable supply for diagnostic imaging − BELOIT, Wis., May 11, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic […]
Read more »
May 4, 2021
Press Releases
BELOIT, Wis., May 4, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present a corporate overview at the Emerging Medtech Summit 2021, on May […]
Read more »
April 13, 2021
Press Releases
− NorthStar has provided reliable molybdenum-99 (Mo-99)/technetium-99m (Tc-99m) supply for more than two years as the only U.S. commercial Mo-99 producer − Second NorthStar Mo-99 production and processing facility nearing completion ensuring even more reliable supply and additional Mo-99 production capability − RadioGenix® System sales continue growth, reliably providing hundreds of thousands of Tc-99m doses […]
Read more »
March 8, 2021
Press Releases
− Technetium-99m is the daughter isotope of molybdenum-99 (Mo-99) – − Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron beam accelerators − − Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world – BELOIT, […]
Read more »
March 3, 2021
Press Releases
− Organizational change positions NorthStar for next stage of growth and ongoing U.S. molybdenum-99 (Mo-99) production expansion − − NorthStar poised to be first commercial-scale supplier of important therapeutic radioisotopes Copper-67 (Cu-67) and Actinium-225 (Ac-225); Initial specialized SPECT imaging portfolio includes fibrin-targeted FibroScint, with potential indications in cardiovascular disease − BELOIT, Wis., March 3, 2021 […]
Read more »
March 2, 2021
Press Releases
BELOIT, Wis., March 2, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually […]
Read more »
January 6, 2021
Press Releases
− Concentrated molybdenum-98 (cMo-98) enables up to four-fold increase of critical medical radioisotope Mo-99 production in U.S. – − First and only commercial-scale application of innovative cMo-98 production technology – BELOIT, Wis., January 6, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radiopharmaceuticals used for medical imaging and […]
Read more »
December 10, 2020
Press Releases
Wilmette, IL, and Beloit, WI, December 10, 2020– Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase plasminogen activator receptor targeted radio-immuno-therapeutic (uPRIT) for the potential treatment of severe COVID-19, today announced the selection of a uPRIT clinical candidate. Monopar and NorthStar partnered with IsoTherapeutics Group LLC to […]
Read more »
December 8, 2020
Press Releases
BELOIT, Wis. – December 8, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Biotech Showcase™ 2021, being delivered digitally January 11 ‒ 15, 2021. Biotech Showcase is an investor conference focused on driving advances […]
Read more »
October 5, 2020
Press Releases
BELOIT, Wis., October 5, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the promotion of Chief Financial Officer Paul Estrem, to Executive Vice President. Mr. Estrem has also been appointed to the NorthStar Board of Managers, effective October 12, 2020, and […]
Read more »
September 17, 2020
Press Releases
BELOIT, Wis., September 17, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that Deputy Secretary of Energy Mark W. Menezes visited the Company’s Beloit, Wis. headquarters on September 11, 2020. His travel to Wisconsin underscored the Department of Energy’s commitment to […]
Read more »
September 9, 2020
Press Releases
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 – Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uPRITs) for the potential treatment of patients with severe COVID-19, today announced a collaboration with The University of Texas Health Science Center at Tyler […]
Read more »
August 10, 2020
Press Releases
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of Radio-Immuno-Therapeutics (RITs) to treat patients with severe COVID-19, today announced a partnership with IsoTherapeutics Group, LLC (Angleton, TX), to develop […]
Read more »
July 23, 2020
Press Releases
July 23, 2020 Statement Attributable to: Stephen Merrick, President and CEO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes supplies a medically critical isotope pair, Mo-99 and Tc-99m, which is used in more than 40,000 U.S. diagnostic imaging procedures daily. Information provided by these scans informs the care and treatment of patients with heart disease and cancer, […]
Read more »
July 8, 2020
Press Releases
BELOIT, Wis. – July 8, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced its participation in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) webinar, “Industry Outlook on Current and Future Mo-99 Supply.” James Harvey, PhD, Chief Scientific Officer of […]
Read more »
June 16, 2020
Press Releases
Chicago, IL and Beloit, WI, June 16, 2020 – Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today a 50/50 collaboration to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19 (patients with SARS-CoV-2 infection). Monopar is a clinical-stage biopharmaceutical company and NorthStar is a commercial producer and supplier […]
Read more »
April 14, 2020
Press Releases
– Award Recognizes Outstanding Contributions to Isotopes and Their Uses to Benefit Mankind – BELOIT, Wis., April 14, 2020 — NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it has received the President’s Award from the World Council on Isotopes (WCI). The […]
Read more »
March 20, 2020
Press Releases
March 19, 2020 Statement Attributable to: Stephen Merrick, President and CEO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes supplies a medically critical isotope pair, Mo-99 and Tc-99m, which is used in more than 40,000 U.S. diagnostic imaging procedures daily. Information provided by these scans informs the care and treatment of patients with heart disease and cancer, […]
Read more »
March 16, 2020
Press Releases
Highlights include: Company marks reliable U.S. Mo-99 production and supply for customers despite ongoing domestic industry supply shortages FDA approval of RadioGenix System version 1.2 enhancements Initiatives for increased domestic Mo-99 production capacity on track: U.S. Food and Drug Administration (FDA)-approved Mo-99 filling lines; isotope processing and accelerator production facilities construction on schedule Strategic acquisition […]
Read more »
March 3, 2020
Press Releases
− Acquisition of technetium-99m (Tc-99m) SPECT agent expands company portfolio as strategic complement to commercially available RadioGenix® System − − Builds on NorthStar’s leadership expertise in development and commercialization of novel radiopharmaceuticals – − Exploratory Phase 1 study planned to investigate FibroScint (Tc-99m F4A) use in identifying thrombus in heart failure patients with assisted devices; […]
Read more »
February 18, 2020
Press Releases
− State-of-the art equipment to increase production efficiency and output for U.S.-based Mo-99 supply – Beloit, Wis., February 18, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved the addition of two […]
Read more »
February 11, 2020
Press Releases
BELOIT, Wis. and Sydney, Australia – February 11, 2020 – NorthStar Medical Technologies, LLC (NorthStar), a global innovator in the production and distribution of radioisotopes used for medical imaging, and Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, today announced the signing of a Letter of Intent for the commercial supply […]
Read more »
January 21, 2020
Press Releases
BELOIT, Wis. – January 21, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Emerging Medtech Summit 2020 conference, being held February 18 ‒ 20, 2020, in Dana Point, Ca. The Emerging Medtech Summit 2020 […]
Read more »
December 16, 2019
Press Releases
BELOIT, Wis. – December 16, 2019 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Biotech Showcase™ 2020, being held January 13 ‒ 15, 2020, in San Francisco, Ca. Biotech Showcase is an investor conference focused […]
Read more »
November 27, 2019
Press Releases
− RadioGenix® Systems have enabled reliable technetium 99m (Tc-99m) supply for patients’ diagnostic imaging procedures since product launch, despite ongoing industry supply shortages – Beloit, Wis., November 27, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, announced a landmark for its RadioGenix System […]
Read more »
October 15, 2019
Press Releases
– Marking NorthStar expansion progress to increase U.S. production of non-highly enriched uranium produced molybdenum-99 (Mo-99), used in producing important medical isotope technetium-99m (Tc-99m) ‒ ‒ Recognizing RadioGenix® System contributions in addressing ongoing Mo-99 supply shortages by providing customers with nearly a year of continuous medical radioisotope supply since launch ‒ Beloit, Wis., October 14, […]
Read more »
September 9, 2019
Press Releases
‒ Voting Begins September 9, 2019 at www.madeinwis.com ‒ Beloit, Wis., September 9, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced its participation in the 4th Annual Coolest Thing Made in Wisconsin contest. The event highlights Wisconsin’s vibrant manufacturing industry, its […]
Read more »
August 28, 2019
Press Releases
‒ Panel to discuss domestic Tc-99m radioisotope production, role of nuclear diagnostics and treatments in advancing personalized medicine – BELOIT, Wis. – August 28, 2019 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Atoms for […]
Read more »
August 20, 2019
Press Releases
Beloit, Wis. and W. Lafayette, Ind., August 20, 2019 – NorthStar Medical Radioisotopes, LLC and Purdue University’s College of Pharmacy today announced a collaborative agreement which expands the College of Pharmacy’s nuclear pharmacy training program. As part of the collaboration, NorthStar has provided a RadioGenix® System to the College of Pharmacy for use in training […]
Read more »
July 23, 2019
Press Releases
– Supports enhancements for commercially available RadioGenix® System and technology to increase NorthStar’s current production capacity of non-uranium based Mo-99 – BELOIT, Wis. – July 23, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it has been awarded $15 million […]
Read more »
July 17, 2019
Press Releases
─ Facility part of staged, dual production pathway plan to expand Mo-99 production and efficiency in parallel with RadioGenix® System enhancements ─ RadioGenix System customers provided with reliable Mo-99 supply throughout eight months since commercial launch, helping mitigate concurrent industry disruptions BELOIT, Wis. – July 16, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator […]
Read more »
June 12, 2019
Press Releases
BELOIT, Wis. – June 12, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced upcoming presentations at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 22 – 26, 2018 in Anaheim, Ca. Presentation topics encompass ongoing domestic […]
Read more »
April 23, 2019
Press Releases
BELOIT, Wis. – April 23, 2019 – NorthStar Medical Technologies, LLC, (“NorthStar” or the “Company”) a global innovator in the production and distribution of radioisotopes used for medical imaging and therapy, today announced the closing of a $100 million secured financing with funds managed by Oberland Capital Management LLC (“Oberland Capital”). NorthStar received $75 million […]
Read more »
March 29, 2019
Press Releases
– Accelerator technology key component of NorthStar’s multi-pronged Mo-99 production strategy – BELOIT, Wis. – March 29, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, and IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment […]
Read more »
February 5, 2019
Press Releases
– Positive RadioGenix System market momentum continues – – Increasing weekly domestic production of non-uranium based Mo-99 – Highlights include: Strategically-planned RadioGenix System roll out on track; initial units in use Numerous RadioGenix System commercial sites in regulatory licensure review process; many additional sites anticipated in 2019 Every week, an increasing number of technetium-99m (Tc-99m) […]
Read more »
December 18, 2018
Press Releases
BELOIT, Wis. – December 18, 2018 –NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced the appointment of Paul Estrem, CPA, as Senior Vice President and Chief Financial Officer. Mr. Estrem holds financial responsibility for the operations of company, reporting to President and Chief […]
Read more »
October 1, 2018
Press Releases
– Award for Outstanding Achievement presented at 2018 Molybdenum-99 Topical Meeting – Beloit, Wis., October 1, 2018 – NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it received an Award for Outstanding Achievement from the U.S. Department of Energy’s National Nuclear Security […]
Read more »
September 17, 2018
Press Releases
– Former Chairman and CEO George Messina named Chairman Emeritus; appointed President and Chief Executive Officer of NorthStar Nuclear Therapies LLC – – Diane Hendricks appointed as Chairperson of the Board – BELOIT, Wis. – Sept. 14, 2018 – The Board of Managers of NorthStar Medical Technologies, LLC (“NorthStar” or the “Company”), a global innovator […]
Read more »
July 24, 2018
Press Releases
– Approval enables expanded manufacturing capacity and supports commercial launch of RadioGenix Systems to produce critically important diagnostic imaging radioisotope technetium-99m from domestic, non-uranium based molybdenum-99 – BELOIT, Wis. – July 24, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in the production and distribution of radioisotopes used for medical imaging, today announced […]
Read more »
June 19, 2018
Press Releases
BELOIT, Wis. – June 19, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in a panel session on molybdenum-99 (Mo-99) supply at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 23 […]
Read more »
June 18, 2018
Press Releases
BELOIT, Wis. – June 18, 2018 – NorthStar Medical Technologies (NorthStar), a company involved in the development, production and distribution of radioisotopes for medical imaging and therapeutics, today provided a progress update on its actinium-225 (Ac-225) radioisotope program. Ac-225 is a high energy alpha-emitting radioisotope with potential therapeutic applications as a Targeted Alpha Therapy (TAT) […]
Read more »
April 30, 2018
Press Releases
– Event recognizes recent U.S. Food and Drug approval of NorthStar’s RadioGenix™ System for use in producing the widely used medical isotope technetium-99m (Tc-99m) from non-uranium produced molybdenum-99 (Mo-99), the first domestic production in more than 25 years – BELOIT, Wis. – April 30, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in […]
Read more »
February 8, 2018
Press Releases
– Enables domestic Mo-99 supply produced without uranium for U.S. healthcare – – First U.S. source of medical radioisotope Mo-99 in more than 25 years – BELOIT, Wis. – February 8, 2018 – NorthStar Medical Radioisotopes, LLC, (NorthStar) a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food […]
Read more »
March 23, 2017
Press Releases
Holst has more than 25 years of sales and marketing experience in the pharmaceutical and medical imaging industries, most recently as senior director of marketing at Navidea Biopharmaceuticals. She joins NorthStar as it advances toward U.S. Food and Drug Administration (FDA) approval of its RadioGenix™ intelligent isotope separation system and its non-fission, non-uranium-based brand of […]
Read more »
December 20, 2016
Press Releases
BELOIT, Wis. – NorthStar Medical Technologies LLC, parent company of NorthStar Medical Radioisotopes LLC, has received additional matching funds from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA), bringing to $11.1 million the total funded for NorthStar Medical Radioisotopes’ accelerator method of producing the medical radioisotope molybdenum-99 (Mo-99). The award supports the process’ […]
Read more »
September 13, 2016
Press Releases
ST. LOUIS (Sept. 13, 2016) – At the National Nuclear Security Administration’s (NNSA) 2016 Mo-99 Topical Meeting in St. Louis, NorthStar Medical Radioisotopes LLC Senior Vice President and Chief Science Officer James Harvey, Ph.D. will report on the company’s progress toward establishing a domestic supply of the medical radioisotope molybdenum-99 (Mo-99) produced without the use […]
Read more »
September 12, 2016
Press Releases
BELOIT, Wis. (Sept. 12, 2016) – NorthStar Medical Radioisotopes LLC has hired James Brodack as vice president of regulatory affairs/quality assurance and Rim Milunas as vice president of engineering. Brodack oversees day-to-day regulatory and quality operations at NorthStar. Milunas spearheads research and development. product design and engineering, with a strong focus on product development and […]
Read more »
June 10, 2016
Press Releases
BELOIT, Wis. (June 10, 2016) – NorthStar Medical Radioisotopes LLC has been awarded three patents and a trademark approval from the United States Patent and Trademark Office. Patents were granted for the RadioGenix™ isotope separation system and two of its key components – the Molybdenum-99 (Mo-99) Source Vessel and the Technetium-99m (Tc-99m) Product Cartridge. A […]
Read more »
May 11, 2016
Press Releases
BELOIT, Wis. – NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research Reactor (MURR) in Columbia, Missouri, adding a new filling line that will quadruple the company’s capacity there to dispense the medical radioisotope molybdenum-99 (Mo-99). NorthStar has contracted with Von Gahlen International Inc. to design and install the system, which will include […]
Read more »
May 2, 2016
Press Releases
BELOIT, Wis. – Stephen Merrick has joined NorthStar Medical Radioisotopes LLC as Senior Vice President and Chief Operating Officer, a newly created position with the company. Merrick brings 24 years of experience in the biotechnology/pharmaceutical/life sciences sector, having held multiple executive positions with leading global companies. He will oversee day-to-day operations at NorthStar – including engineering, production and customer […]
Read more »
October 22, 2015
Press Releases
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has received $11.75 million from the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA) for continued development and commercialization of two technologies to produce the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). NNSA provided $8.86 million to support NorthStar’s neutron capture production process and $2.89 million for the company’s accelerator production process. […]
Read more »
September 9, 2015
Press Releases
MADISON, Wis. – NorthStar Medical Radioisotopes LLC and the Westinghouse Electric Company LLC have completed a memorandum of understanding under which the companies will explore the potential for producing medical radioisotopes in commercial nuclear reactors. Of particular interest is the generation of molybdenum-99 (Mo-99) via the irradiation of molybdenum-98 (Mo-98) in the commercial nuclear reactor core. This collaboration is […]
Read more »
August 31, 2015
Press Releases
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has received approval to begin routine production of molybdenum-99 (Mo-99) at the University of Missouri Research Reactor (MURR) facility in Columbia, Mo. The company will now be able regularly operate its proprietary aliquoting system at the MURR site to fill source vessels with Mo-99, enabling the company to establish a weekly production […]
Read more »
May 6, 2015
Press Releases
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has completed its first production-scale test run of the molybdenum-99 (Mo-99) aliquoting system installed at the University of Missouri Research Reactor (MURR) in Columbia, Missouri. The test and subsequent shipment of the resulting Mo-99 to NorthStar’s Madison facility is another milestone in the establishment of domestic production of the vital medical radioisotope. […]
Read more »
March 10, 2015
Press Releases
MADISON, Wis. – James Harvey, Ph.D., senior vice president and chief science officer of NorthStar Medical Radioisotopes LLC, will be a featured speaker at the American Pharmacists Association Annual Meeting & Exposition (APhA2015) in San Diego later this month, highlighting new technologies and techniques that will create a commercially viable domestic supply of the medical radioisotope molybdenum-99 (Mo-99). Harvey […]
Read more »
November 14, 2014
Press Releases
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has been awarded $5.2 million in additional funding by the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The grant supports the continued development and commercialization of the company’s neutron capture process for producing the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). Under the terms of the cooperative agreement […]
Read more »
August 14, 2014
Press Releases
Madison, Wis. – August 14, 2014 – NorthStar Medical Radioisotopes LLC has signed a non-exclusive letter of intent with GE Healthcare, a division of General Electric Company (NYSE: GE), marking further progress toward establishing the first existing commercially viable domestic source of the radioisotope 99molybdenum (99Mo). 99Mo is the parent isotope of 99mtechnetium (99mTc), the most widely […]
Read more »
July 22, 2014
Press Releases
BELOIT, Wis. – July 22, 2014 – NorthStar Medical Radioisotopes LLC broke ground today for a new 50,000-square-foot facility at 1800 Gateway Blvd. in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99). Video Courtesy WKOW News NorthStar Medical Radioisotopes Breaks Ground […]
Read more »
July 15, 2014
Press Releases
WASHINGTON, D.C. – July 15, 2014 – NorthStar Medical Radioisotopes LLC is making continued progress towards establishing a commercially viable domestic supply of the radioisotope molybdenum-99 (Mo-99), according to NorthStar’s chief science officer, James T. Harvey, Ph. D. Harvey provided an update on NorthStar’s progress in two presentations at the 2014 Mo-99 Topical Meeting here, […]
Read more »
June 30, 2014
Press Releases
MADISON, Wis. – June 30, 2014 – NorthStar Medical Radioisotopes LLC has signed a pledge with the Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO) designed to help the CTBTO detect nuclear testing. In signing the Radioxenon Emissions Pledge, NorthStar stated that its production of the medical radioisotope molybdenum-99 (Mo-99) does not result in the emission […]
Read more »
June 7, 2014
Press Releases
ST. LOUIS, MO – June 7, 2014 – Signaling progress in the drive to launch the first commercially-viable domestic source of non-HEU materials, NorthStar Medical Technologies, LLC today announced the signing of a non-exclusive Letter of Intent with Triad Isotopes, Inc. The agreement solidifies Triad’s position as an early adopter of domestically-sourced Non-HEU Molybdenum99 through […]
Read more »
November 21, 2013
Press Releases
MADISON, WI – November 21, 2013 – NorthStar Medical Technologies, LLC (“NorthStar”), today announced it was awarded a $21.8 million cooperative agreement of which $10.9 million will be funded by the Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The cooperative agreement is part of the NNSA’s Global Threat Reduction Initiative, which aims to […]
Read more »
September 17, 2013
Press Releases
MADISON, WI – September 17, 2013 – NorthStar Medical Technologies, LLC (“NorthStar”), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine industry, today announced the closing of a financing round totaling $13.5 million. The round was led by NorthStar’s lead investor, Hendricks Holding Company, Inc., and a group of accredited local investors. Proceeds […]
Read more »
March 20, 2013
Press Releases
MADISON, WI – March 20, 2013 – NorthStar Medical Technologies, LLC, (NorthStar) announced that it has submitted a New Drug Application (NDA) with the Food and Drug Administration (FDA). The FDA has accepted the application for review. The submission is for NorthStar’s TechneGen™ Generator System, which will allow nuclear pharmacies to process radioisotopes for critical medical […]
Read more »
November 15, 2012
Press Releases
MADISON, WI. – November 15, 2012 – NorthStar Medical Radioisotopes, LLC (NorthStar), today announced that it has been awarded $22.2 million in federal funding in a Phase 2 cooperative agreement through the National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative. The cooperative agreement marks successful completion of an Environmental Assessment of NorthStar’s proposed Beloit, Wis. facility. […]
Read more »
September 26, 2012
Press Releases
MADISON, WI – September 26, 2012 – NorthStar Medical Technologies, LLC (NorthStar), today announced that it has signed an agreement with Hendricks Commercial Properties, LLC (HCP) to develop a state-of-the-art medical isotope production facility in the Gateway Business Park of Beloit, Wisconsin. The facility will be built to suit for lease. Once complete, the facility […]
Read more »
September 5, 2012
Press Releases
MADISON, WI – September 5, 2012 – NorthStar Medical Technologies, LLC (NorthStar), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine field, today announced the closing of a Series D preferred stock financing round totaling $5.2 million. Stateline Angel Investors of Rockford, Illinois, was the lead investor, joined by existing NorthStar investor Hendricks […]
Read more »
November 1, 2011
Press Releases
(MADISON, Wis. – Nov. 1, 2011) – NorthStar Medical Radioisotopes, LLC (NMR) has signed a follow on cooperative agreement totaling $4.6 million with the National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative for the company’s medical isotope production program. The cooperative agreement will be funded under a 50-50 cost share arrangement between NMR and […]
Read more »
September 12, 2011
Press Releases
WILMINGTON, N.C.—September 12, 2011—To help address a shortage of molybdenum-99 (Mo-99), a medical isotope used in millions of medical procedures each year, GE Hitachi Nuclear Energy (GEH) and Exelon have joined to study the feasibility of producing Mo-99 at Clinton Power Station, a nuclear power plant in Clinton, Ill. Mo-99 decays into technetium-99m, an isotope […]
Read more »
September 8, 2011
Press Releases
MADISON, Wis. –Sept. 8 — NorthStar Medical Radioisotopes was among six Wisconsin bioscience companies to be selected as the winners of BioForward’s 2011 Emerging Company Showcase. The showcase is part of the 2011 Bioscience Vision Summit, hosted by BioForward, the member-driven state association that is the voice of Wisconsin’s bioscience industry. The Emerging Company Showcase […]
Read more »
April 7, 2011
Press Releases
(MADISON, WI. – April 7, 2011) – NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has received an investment from Hendricks Holdings of Beloit, WI. The investment will allow NorthStar to rapidly pursue introduction of new technologies and production methodologies in the nuclear medicine market for molybdenum-99 and other medically significant radioisotopes. Molybdenum-99 is used to […]
Read more »
March 1, 2011
Press Releases
(MADISON, WI. – March 1, 2011) – NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has signed an agreement with the University of Missouri Research Reactor (MURR) to supply NorthStar with low specific activity molybdenum-99. This agreement allows NorthStar to ramp up over time to 3,000 6-day curies per week. Production operations are expected to begin […]
Read more »
